Hello,

Welcome to our flagship newsletter, MarketBeat Daily Ratings.

We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.

But first, we need you to do two quick things:

1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.

2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report. 

Confirm your subscription here.

After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.

Thank you again for subscribing. We look forward to being an important part of your investing journey

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.

(ARReply-161)

What Might It Take for D-Wave to Reset Its Course?

Authored by Nathan Reiff. Posted: 9/14/2026.

2026 has brought periods of significant momentum for quantum computing giant D-Wave Quantum Inc. (NASDAQ: QBTS), driven by investor enthusiasm surrounding the technology's growing commercial adoption. However, a more dominant theme this year may be D-Wave's seemingly perpetual decline, which has ultimately left shares down about 40% since Jan. 1.

Late summer has brought renewed skepticism as investors reassess D-Wave's financial performance and how the company compares with other quantum names in a highly competitive environment.

Moderna surged nearly 200 percent in a day on trial news (Ad)

Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news.

Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.

Stream the free Ignition Point broadcast for the full biotech breakdown.

To be sure, QBTS shares remain well above where they traded just a few years ago. However, the recent correction highlights a major challenge for the company: Investors want to see measurable commercial success to accompany promising technological advancements and hype.

To reverse course and return to an upward share price trajectory, D-Wave will likely need to demonstrate meaningful revenue acceleration, expanding gross margins, expense control and strong product execution. Some of these goals may be more achievable than others.

Last Month's Drop Erases Earlier Gains

With shares down 17% over the last month, D-Wave has given back a significant portion of its gains this year. The major catalyst for this recent weakness was the firm's Q2 2026 earnings report, which showed disappointing revenue of $3.1 million, below the forecast of $4 million. Revenue also declined by less than 1% year over year, even as many other quantum firms reported triple-digit improvement over the same period.

A closer look reveals legitimate reasons for the quarter's revenue slump—namely, anticipated customer deals failed to close or be recorded during the period. This suggests that D-Wave's sales remain sporadic and concentrated among a small number of clients. Nonetheless, the market was unwilling to look past the weakness and punished the stock as a result.

D-Wave Is Still Very Promising, But Investors May Be Impatient

Just a few quarters ago, quantum computing firms tended to rise and fall closely together, as enthusiasm for one company's achievements carried over to the share prices of its rivals. Now, however, the industry is growing larger, and companies are differentiating themselves to a greater degree. When a rival like IonQ Inc. (NYSE: IONQ) can post stellar earnings results while D-Wave investors have to search for bright spots in a quarterly report, the market rewards the winner.

While this does not change the fact that D-Wave's bookings, cash position and many other metrics remain strong, the divergence illustrates that the shift taking place in the quantum industry is real. Recurring revenue, overall revenue growth, commercial traction, improving financial visibility and disciplined expenses are all ways companies in the industry can now distinguish themselves.

How D-Wave May Use Its Advantages

D-Wave has several important competitive advantages. Its quantum annealing strategy may lend itself to a wide range of optimization-focused commercial applications. Its dual approach, which also includes more traditional gate-model technology, provides crucial diversification in an R&D race whose final outcome no one can predict with certainty.

Still, technological differentiation alone is no longer enough to keep investors satisfied. Instead, the company needs to find ways—most likely in future quarterly reports—to show hard evidence of financial progress. In recent weeks, there have been some potentially promising signs, including an announcement from the U.S. Department of Commerce that D-Wave would receive up to $100 million as part of a broader investment in the quantum computing industry.

Government funding could provide numerous benefits, not only by supplying non-dilutive capital for D-Wave's many R&D initiatives but also by providing external validation of the company's technological and operational successes to date. It will not immediately transform the company's financials, but it may nonetheless accelerate some of its goals while strengthening customer confidence in the firm.

Perhaps the single biggest factor for D-Wave is accelerating quarterly revenue. Closing long-term contracts is all well and good, but to achieve greater consistency, the firm may be best served by demonstrating recurring revenue, either through subscription sales for its cloud-based products or through larger, multiyear contracts with more predictable payment schedules.

Analysts remain bullish on QBTS stock overall, and shares have massive upside potential based on consensus price estimates. However, that potential may not be enough without hard evidence of sales success to show that D-Wave is keeping pace with its competitors in the industry.